Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sutro Biopharma Inc STRO

Healthcare Biotechnology
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs... see more

Recent & Breaking News (NDAQ:STRO)

Sutro Biopharma Appoints Greg Chow as Chief Financial Officer

GlobeNewswire 12 days ago

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

GlobeNewswire May 8, 2025

Sutro Biopharma to Participate in Upcoming Investor Conferences

GlobeNewswire May 1, 2025

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

GlobeNewswire April 28, 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

GlobeNewswire March 15, 2025

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

GlobeNewswire March 13, 2025

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

GlobeNewswire March 13, 2025

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire March 3, 2025

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference 

GlobeNewswire January 7, 2025

Sutro Biopharma and Boehringer Ingelheim BioXcellence(TM) collaboration: Established first-in-class cell-free capabilities at commercial scale

GlobeNewswire January 7, 2025

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

GlobeNewswire December 10, 2024

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

GlobeNewswire November 13, 2024

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

GlobeNewswire November 4, 2024

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

GlobeNewswire November 1, 2024

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

GlobeNewswire October 10, 2024

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 20, 2024

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

GlobeNewswire September 14, 2024

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

GlobeNewswire September 11, 2024

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

GlobeNewswire August 22, 2024

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

GlobeNewswire August 13, 2024